অস্ট্রেলিয়া - ইংরেজি - APVMA (Australian Pesticides and Veterinary Medicines Authority)

kd plant care pty ltd - phosphorous acid present as mono-di potassium phosphite - soluble concentrate - phosphorous acid present as mono-di potassium phosphite mineral-phosphorus-acid active 400.0 g/l - fungicide - avocado | citrus - mature, well established | citrus - young or small | cucurbit | grape | ornamental | pineapple | subterranean - downy mildew | phytophthora collar rot | phytophthora root rot | soil fungi

অস্ট্রেলিয়া - ইংরেজি - APVMA (Australian Pesticides and Veterinary Medicines Authority)

kd plant care pty ltd - chlorpropham - dust - chlorpropham carbamate-phenylcarbamate active 25.0 g/kg - plant regulator - stored potato | stored table potato - prevention of sprouting

আয়ার্লণ্ড - ইংরেজি - HPRA (Health Products Regulatory Authority)

merz pharmaceuticals gmbh - clostridium botulinum neuro-toxin type a (150 kd), free from complexing proteins - powder for solution for injection - 50 - other muscle relaxants, peripherally acting agents; botulinum toxin

আয়ার্লণ্ড - ইংরেজি - HPRA (Health Products Regulatory Authority)

merz pharmaceuticals gmbh - clostridium botulinum neuro-toxin type a (150 kd), free from complexing proteins - powder for solution for injection - 100 - other muscle relaxants, peripherally acting agents; botulinum toxin

আয়ার্লণ্ড - ইংরেজি - HPRA (Health Products Regulatory Authority)

merz pharmaceuticals gmbh - clostridium botulinum neuro-toxin type a (150 kd), free from complexing proteins - powder for solution for injection - 200 - other muscle relaxants, peripherally acting agents; botulinum toxin

আয়ার্লণ্ড - ইংরেজি - HPRA (Health Products Regulatory Authority)

croma-pharma gmbh - clostridium botulinum neurotoxin type a (900 kd) - powder for solution for injection - botulinum toxin

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - rituximab, quantity: 100 mg - injection, concentrated - excipient ingredients: polysorbate 80; water for injections; sodium chloride; sodium citrate dihydrate - non-hodgkin?s lymphoma truxima is indicated for treatment of patients with: -cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin?s lymphoma; - cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma; - cd20 positive, diffuse large b-cell non-hodgkin?s lymphoma, in combination with chemotherapy.,chronic lymphocytic leukaemia truxima is indicated for the treatment of patients with cd20 positive chronic lymphocytic leukaemia (cll) in combination with chemotherapy.,rheumatoid arthritis truxima (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (tnf) inhibitor therapy. truxima has been shown to reduce the rate of progression of joint damage as measured by xray when given in combination with methotrexate.,granulomatosis with polyangiitis (wegener?s) (gpa) and microscopic polyangiitis (mpa) truxima in combination with glucocorticoids is indicated for the induction of remission in patients with severely active granulomatosis with polyangiitis (gpa, also known as wegener?s granulomatosis) and microscopic polyangiitis (mpa). the efficacy and safety of retreatment with rituximab have not been established.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - rituximab, quantity: 500 mg - injection, concentrated - excipient ingredients: sodium citrate dihydrate; polysorbate 80; water for injections; sodium chloride - non-hodgkin?s lymphoma truxima is indicated for treatment of patients with: -cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin?s lymphoma; - cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma; - cd20 positive, diffuse large b-cell non-hodgkin?s lymphoma, in combination with chemotherapy.,chronic lymphocytic leukaemia truxima is indicated for the treatment of patients with cd20 positive chronic lymphocytic leukaemia (cll) in combination with chemotherapy.,rheumatoid arthritis truxima (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (tnf) inhibitor therapy. truxima has been shown to reduce the rate of progression of joint damage as measured by xray when given in combination with methotrexate.,granulomatosis with polyangiitis (wegener?s) (gpa) and microscopic polyangiitis (mpa) truxima in combination with glucocorticoids is indicated for the induction of remission in patients with severely active granulomatosis with polyangiitis (gpa, also known as wegener?s granulomatosis) and microscopic polyangiitis (mpa). the efficacy and safety of retreatment with rituximab have not been established.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

allergan australia pty ltd - botulinum toxin - type a; botulinum toxin, type a; botulinum toxin, type a -

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate -